Presentation LAA 2017 The Multifaceted Etiology of Stroke: Focus on Atrial Fibrillation and PFO Presenter: M. Edip Gurol July 21, 2017
Presentation TVT 2017 Managing AS Patients With Atrial Fibrillation After TAVR Pharmacotherapy Considerations and LAAC Possibilities Presenter: Samir R. Kapadia June 16, 2017
Presentation Prevalence, Management, and Long-term (6-Year) Outcomes of A-fib Among Patients Receiving DES May 23, 2017
Presentation EuroPCR 2017 Routine Fractional Flow Reserve Measurement after Percutaneous Coronary Intervention The FFR-SEARCH Study Presenter: Roberto Diletti May 18, 2017
Presentation SWVS 2017 Atrial Fibrillation After SAVR: Optimizing management of peri-TAVR AF Presenter: Ankur Kalra May 06, 2017
Presentation SIF 2017 Thromboembolic Prophylaxis in Atrial Fibrillation Presenter: Samir Kapadia March 09, 2017
Presentation CRT 2017 Triple Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement Presenter: Chadi Alraies February 22, 2017
Presentation Apixaban in Patients With Atrial Fibrillation After TAVR Presenter: J. Seeger January 03, 2017
Presentation AHA 2016 PIONEER Trial: An OPen-label, Randomized, Controlled, Multicenter Study ExplorIng TwO TreatmeNt StratEgiEs of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy Presenter: Michael Gibson November 15, 2016
Presentation TCT 2016 AMULET OBSERVATIONAL STUDY: Multicenter, Prospective, Registry Results With a Left Atrial Appendage Closure Device for Stroke Prevention in Patients With Atrial Fibrillation Presenter: Martin B. Leon, Louis A. Cannon, David Hildick-Smith November 02, 2016
Presentation TCT 2016 WATCHMAN US POST-APPROVAL STUDY: Multicenter, Prospective, Registry Results With a Left Atrial Appendage Closure Device for Stroke Prevention in Patients With Atrial Fibrillation Presenter: Martin B. Leon, Louis A. Cannon, David R. Holmes Jr. November 02, 2016
Presentation TCT 2016 Is Ablation an Alternative to Triple Therapy in Patients With Atrial Fibrillation and PCI or ACS? Presenter: Martin W. Bergmann, Samir R. Kapadia, Vivek Y. Reddy November 01, 2016
Presentation TCT 2016 Should the New Oral Anticoagulants (vs Warfarin) Change the Equation of Triple Therapy vs LAA Closure? Presenter: Martin W. Bergmann, Samir R. Kapadia, Harvey D. White November 01, 2016
Presentation TCT 2016 Selecting the Right LAA Closure Device Based on Patient Characteristics and LAA Anatomy: Occluder, Ligation, or Clipping Presenter: Martin W. Bergmann, Samir R. Kapadia, Jason H. Rogers November 01, 2016
Presentation TCT 2016 Is LAA Closure an Alternative to Triple Therapy for all Patients or Those at High Bleeding Risk? Current Dataset Presenter: Martin W. Bergmann, Samir R. Kapadia, Brian K. Whisenant November 01, 2016
Presentation TCT 2016 Why Triple Therapy? Rationale and Potential Role for LAA Closure in the PCI Patient Presenter: Martin W. Bergmann, Samir R. Kapadia, Ashish Pershad November 01, 2016
Presentation TCT 2016 The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status Presenter: Freek W.A. Verheugt, Pascal Vranckx, Deepak L. Bhatt November 01, 2016
Presentation TCT 2016 The AUGUSTUS Trial: Apixaban in Patients With Atrial Fibrillation and ACS/PCI: Design, Rationale, and Status Presenter: Freek W.A. Verheugt, Pascal Vranckx, Roxana Mehran November 01, 2016